

Contents

Part I Introduction

- 1 Need for Optimal Design of Pharmaceutical Programs and Portfolios in Modern Medical Product Development.....** 3
Zoran Antonijevic

Part II Background

- 2 Clinical Aspects of Pharmaceutical Portfolio Management.....** 19
Frederic (Rick) Sax, Raymond A. Huml, and Judith Ng-Cashin
- 3 Drug Development and the Cost of Capital.....** 35
Kraig F. Schulz, Sarah T. Bobulsky, Frank S. David,
Nitin R. Patel, and Zoran Antonijevic
- 4 Investment Considerations for Pharmaceutical Product Portfolios** 49
Raymond A. Huml
- 5 Challenges of Portfolio Management in Pharmaceutical Development** 71
Charles Persinger

Part III Quantitative Methodology

- 6 Impact of Phase 2b Strategies on Optimization of Drug Development Programs** 83
Zoran Antonijevic, Jim Bolognese, Carl-Fredrik Burman,
Christy Chuang-Stein, Chris Jennison, Martin Kimber,
Olga Marchenko, Nitin R. Patel, and José Pinheiro

7	Using Decision Analysis to Support the Design of Clinical Trials Within a Program.....	105
	Richard Nixon and Blair Ireland	
8	Indication Sequencing for a New Molecular Entity with Multiple Potential Oncology Indications.....	123
	Jack Kloeber Jr., Alex Stojanovic, and C. Kwon Kim	
9	Maximizing Return on Investment in Phase II Proof-of-Concept Trials.....	141
	Cong Chen, Robert A. Beckman, and Linda Z. Sun	
10	Portfolio Optimization of Therapies and Their Predictive Biomarkers	155
	Robert A. Beckman and Cong Chen	
11	Dynamically Optimizing Budget Allocation for Phase 3 Drug Development Portfolios Incorporating Uncertainty in the Pipeline.....	181
	Nitin R. Patel and Suresh Ankolekar	
	Index.....	201

Optimization of Pharmaceutical R&D Programs and
Portfolios

Design and Investment Strategy

Antonijevic, Z. (Ed.)

2015, VIII, 202 p. 38 illus., 24 illus. in color., Hardcover

ISBN: 978-3-319-09074-0